Among patients with low-grade, intermediate-risk NMIBC, UGN-102 generated robust, durable responses in an analysis of the ...

The Bladder Cancer Company, announces the presentation on February 14 of a new abstract with study results from its U.S. bladder cancer patient registry at the 2025 American Society of Clinical ...

Rondo Therapeutics, a privately held biopharmaceutical immuno-oncology company pioneering the development of next-generation ...

New Data at ASCO GU Show Power of Veracyte’s Decipher Tests to Improve Patient Care and Its GRID Tool to Advance Prostate and ...

Data on enfortumab vedotin plus pembrolizumab for advanced bladder cancer, along with updates on antibody-drug conjugates, ...

The Bladder Cancer Company, announces the presentation on February 14 of a new abstract with study results from its U.S.